Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
Physicians with current and valid licenses in the United States, Canada, or Mexico who read any 3 of the selected continuing medical education (CME) articles in this issue of Archives of Dermatology, complete the CME Evaluation Form, and fax it to the number or mail it to the address at the bottom of the CME Evaluation Form are eligible for Category 1 CME credit. There is no charge.
The American Medical Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The AMA designates this educational activity for up to 1 hour of Category 1 credit per Archives of Dermatology issue toward the AMA Physician's Recognition Award (PRA). Each physician should claim only those hours of credit that were actually spent in the educational activity.
Physicians with current and valid licenses in the United States, Mexico, or Canada are eligible for CME credit even if they live or practice in other countries. Physicians licensed in other countries are also welcome to participate in this CME activity. However, the PRA is only available to physicians licensed in the United States, Canada, or Mexico.
To earn credit, read the articles designated for CME credit carefully and complete the CME Evaluation Form. The CME Evaluation Form must be submitted within 3 months of the issue date. A certificate awarding 1 hour of Category 1 CME credit will be faxed or mailed to you; it is then your responsibility to maintain a record of credit received. Questions about CME processing should be directed to The Blackstone Group; tel: (312) 419-0400, ext 225; fax: (312) 269-1636.
One of our goals is to assess continually the educational needs of our readers so we may enhance the educational effectiveness of the Archives of Dermatology. To achieve this goal, we need your help. You must complete the CME Evaluation Form to receive credit.
For a complete description of the ARCHIVES' mission statement, please refer to the table of contents.
A flexible curriculum of article topics is developed annually by the journal's editorial board and is then supplemented throughout the year with information gained from readers, authors, reviewers, and editors. The Reader's Choice CME activity allows readers, as adult learners, to determine their own educational needs and to assist the editors in addressing their needs in future issues.
Readers of the Archives of Dermatology should be able to attain the following educational objectives: (1) select and read at least 3 articles per issue to gain new medical information on topics of particular interest to them as physicians, (2) assess its value to them as practicing physicians, and (3) think carefully about how this new information may influence their own practices.
The following articles in this issue may be read for CME credit:
Psoriasis as a Model for T-Cell–Mediated Disease: Immunobiologic and Clinical Effects of Treatment With Multiple Doses of Efalizumab, an Anti–CD11a AntibodyArticle
Educational Objective: To learn that blocking CD11 improves the conditions of patients with moderate to severe disease.
Histological Characteristics of Metastasizing Thin Melanomas: A Case-Control Study of 43 CasesArticle
Educational Objective: To learn that significant regression is a risk factor and that in situ lesions can metastasize.
Nodular Type and Older Age as the Most Significant Associations of Thick Melanoma in Victoria, AustraliaArticle
Educational Objective: To learn that most thick lesions are seen in older patients and are the nodular subtype.
Pathology Review of Cases Presenting to a Multidisciplinary Pigmented Lesion ClinicArticle
Educational Objective: To learn that pathology review in this setting significantly changed the diagnosis in about 10% of cases.
Reliability of the Histopathologic Diagnosis of Malignant Melanoma in ChildhoodArticle
Educational Objective: To learn that even among experts concordance was poor.
The Effectiveness of Tumor Necrosis Factor α Antibody (Infliximab) in Treating Recalcitrant Psoriasis: A Report of 2 CasesArticle
Educational Objective: To learn about a promising new therapy for severe disease.
Archives of Dermatology Reader's Choice: Continuing Medical Education. Arch Dermatol. 2002;138(5):707-708. doi:10.1001/archderm.138.5.707